MARRA, ANTONIO
MARRA, ANTONIO
Dipartimento di Oncologia ed Emato-Oncologia
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209]
2026 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
2026 G. Mazzoli, L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Fotia, M. De Monte, F. Ligorio, F. Jacobs, G. Armani, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, A.C. Schianca, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
2026 M. Aldea, M. Salto-Tellez, A. Marra, R. Umeton, A. Stenzinger, M. Koopman, A. Prelaj, K.L. Kehl, S. Gilbert, M.-. Lessmann, J. Lipkova, L. Provenzano, F. Meric-Bernstam, S. Halabi, J. Wu, A. Pellat, K.P.M. Suijkerbuijk, B. Besse, B. Ryll, C. Marchio, M. Crispin-Ortuzar, R. Fehrmann, J. Vibert, D. Ferber, C. Pauli, A. Valachis, F. Corso, T.J. Brinker, J. Mateo, N. Harbeck, E.C. Winkler, F. Lopez-Rios, R. Perez-Lopez, G. Pentheroudakis, S. Delaloge, C. Benedikt Westphalen, J.N. Kather
Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer
2026 A. Marra, S.H. Kim, F. Pareja, T. Basili, D.B. Solit, S. Chandarlapaty, G. Plitas, J.S. Reis-Filho, B. Weigelt, T.A. King, D.N. Brown
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
2026 A. Gupta, A. Gazzo, P. Selenica, A. Safonov, F. Pareja, E.M. Da Silva, D.N. Brown, H. Shao, Y. Zhu, J. Patel, J. Blanco-Heredia, B. Stefanovska, M.A. Carpenter, Y. Chen, I. Vegas, X. Pei, D. Frosina, A.A. Jungbluth, M. Ladanyi, G. Curigliano, B. Weigelt, N. Riaz, S.N. Powell, P. Razavi, R.S. Harris, J.S. Reis-Filho, A. Marra, S. Chandarlapaty
Conditional Generative AI in Oncology Diagnostics
2026 C. Frascarelli, A. Concardi, E. Mangione, M. Negrelli, F.M. Porta, M. Tulino, J. Sorino, A. Marra, N. Fusco, E. Guerini-Rocco, K. Venetis
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
2026 A. Safonov, M. Lee, D.N. Brown, L. Boscolo Bielo, M. Mehine, C. Bandlamudi, B. O'Leary, H. Shao, L. Vicente, D. Muldoon, A. Zhu, S. Ros, A. Marra, P. Selenica, I. Bieche, B. Wubbenhorst, E. Ferraro, L. Courtois, R. El Botty, M. Ahmed, E. Moiso, J.A.-. An, M.T.A. Donoghue, M. Will, F. Pareja, E. Nizialek, N. Lukashchuk, E. Sofianopoulou, Y. Liu, X. Huang, C. Chappey, A.D. Staniszewska, D. Ross, D. Mandelker, M. Ladanyi, N. Schultz, M.F. Berger, M. Scaltriti, J.S. Reis-Filho, B.T. Li, K. Offit, L. Norton, R. Shen, K.N. Maxwell, F. Couch, S.M. Domchek, E. Marangoni, S. Shah, M.R. Albertella, V. Serra, B. Weigelt, D.B. Solit, K.L. Nathanson, M.E. Robson, N.C. Turner, S. Chandarlapaty, P. Razavi
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis
2026 P. Zagami, B.T. Salimbeni, E.P. Preti, A. Esposito, A. Marra, D. Trapani, E. Munzone, M. Mazza, S. Martella, I. Durosini, S. Perazzo, R. Marsicano, P.P. Maria Berton Giachetti, G. Curigliano, C. Criscitiello, G. Pravettoni
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions
2026 J. Iranzo, E. Giordano, R.M. Marsicano, D. Trapani, A. Marra, C. Belli, P. Zagami, P.P.M. Berton Giachetti, E. Ferraro, I. Minchella, E. Crimini, G. Curigliano
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano
Current controversies in the use of Oncotype DX in early breast cancer
2025 P.P.M. Berton Giachetti, A.C. Schianca, D. Trapani, A. Marra, A. Toss, C. Marchiò, M.V. Dieci, O.D. Gentilini, C. Criscitiello, K. Kalinsky, J.A. Sparano, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
2025 R. Scafetta, P. Zagami, M. Del Re, C. Criscitiello, A. Marra, G. Curigliano
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives
2025 A. Marra, S. Morganti, F. Pareja, G. Campanella, F. Bibeau, T. Fuchs, M. Loda, A. Parwani, A. Scarpa, J.S. Reis-Filho, G. Curigliano, C. Marchiò, J.N. Kather
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
2025 E. Zattarin, A. Marra, A. Palazzo, G. Griguolo, C. Vernieri, J. Etessami, L. Pontolillo, G. Landa, A. Daneri, M. De Monte, R. Cuoghi Costantini, E. Tenedini, O. Ponzoni, M.G. Razeti, C. Sposetti, E. Barbieri, M. Manni, F. Caggia, L. Cortesi, G. Curigliano, E. Bria, M. Dominici, V. Guarneri, M. Lambertini, A. Toss
Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models
2025 C. Frascarelli, K. Venetis, A. Marra, A. Concardi, M. D'Ercole, E. Mangione, M. Negrelli, F.M. Porta, S. Keswani, G. Curigliano, E. Guerini-Rocco, N. Fusco
Advancing breast cancer therapy in the era of molecular diagnostics
2025 M.G. Carnevale, R.R. Colciago, M.C. De Santis, L. Cortesi, C. De Marco, A. Marra, A. Vingiani, F. Nolè, G. Curigliano, G. Pruneri, A. Llombart-Cussac, S. Di Cosimo, J. Cortes